8-Hydroxy(di-n-propylamino)tetralin (8-
OH-DPAT; 0.1-50 mg/kg i.p.) evoked a dose-dependent
mydriatic response in conscious mice (ED50 = 5.8 mg/kg i.p.) which was maximal after 10 min.
8-OH-DPAT (2 mg/kg i.p.)-induced
mydriasis was attenuated by the alpha 2-adrenoceptor antagonists,
idazoxan (1 and 3 mg/kg i.p.) and
yohimbine (1 and 3 mg/kg i.p.), by the
5-HT1 receptor antagonists,
pindolol (10 mg/kg i.p.) and
quipazine (2 mg/kg i.p.), and by the selective
5-HT1A receptor antagonist, (-)-N-tert-butyl-3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-phenyl
propionamide ((-)-
WAY 100135; 1-10 mg/kg s.c.). These data argue that both central alpha 2-adrenoceptors and 5-HT1A receptors are involved in the mediation of
mydriasis induced by
8-OH-DPAT. The synaptic location of these receptors was determined using either
N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (
DSP-4; 100 mg/kg i.p.) or
5,7-dihydroxytryptamine (5,7-DHT; 75 micrograms i.c.v.)+
p-chlorophenylalanine (PCPA; 200 mg/kg i.p.); these lesioning procedures respectively produced highly significant losses of whole brain
noradrenaline (72% depletion) and
5-HT (78% depletion). The former abolished
8-OH-DPAT (5 mg/kg i.p. (ED50))
mydriasis, whereas the latter was without effect.
8-OH-DPAT (0.5-5 mg/kg i.p.) also dose-dependently increased the
noradrenaline metabolite, 3-methoxy-4-hydroxy-phenylglycol (
MHPG), in mouse whole brain minus cerebellum. Taken together these results show that
8-OH-DPAT initially stimulates 5-HT1A receptors, and it is likely that this is followed by release of
noradrenaline onto postsynaptic alpha 2-adrenoceptors, the latter effect being responsible for the
mydriatic response.